Trial Profile
An Open-Label Therapeutic Exploratory Clinical Trial of HuMax-CD4, a Fully Human Monoclonal Anti-CD4 Antibody, in Patients With Refractory or Persistent Early Stage (IA-IIA) Cutaneous T-Cell Lymphoma
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 22 May 2023
Price :
$35
*
At a glance
- Drugs Zanolimumab (Primary)
- Indications Cutaneous T-cell lymphoma
- Focus Adverse reactions; Therapeutic Use
- Sponsors Genmab
- 14 Sep 2012 New trial record